Why the UAE Is Becoming A Premier Destination For Medical Tourism

by THEFUTURE.TEAM

February 11, 2025

With a commitment to enhancing its healthcare offerings, the UAE has positioned itself as a leader in medical tourism, catering to a growing global demand. As countries focus on improving the health of their populations, the UAE stands out for its strategic investments in both healthcare infrastructure and its appeal to medical tourists.

According to Statista, the global medical tourism market was valued at $47 billion in 2024, with projections indicating it could exceed $111 billion by 2029. The UAE is setting the bar high, with innovative initiatives such as specialized portals for health tourists and streamlined entry processes for medical visitors.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Tailored Portals And Seamless Experiences

Abu Dhabi and Dubai have launched dedicated online platforms that streamline the process for medical tourists. These portals offer a range of services, including healthcare provider contact information, appointment bookings, hotel reservations, and local transportation. Dubai Health Authority (DHA) introduced the Dubai Health Experience (DXH) brand in 2016, aimed at making the city a global leader in health tourism. The platform offers a curated selection of top-tier treatments in fields such as dentistry, fertility, ophthalmology, and cosmetic surgery.

Meanwhile, in 2018, Abu Dhabi’s Department of Health (DoH) rolled out its own e-portal, showcasing a network of over 40 healthcare facilities that meet the stringent quality standards of the DoH’s JAWDA program. Visitors can explore nearly 300 treatment packages across specialties ranging from routine check-ups to complex surgeries.

Simplified Access With Specialized Permits

To further attract international patients, the UAE offers specialized entry permits for medical tourists and their companions. These permits, which can be single or multiple entries, are sponsored by medical institutions and processed by relevant authorities in the country. Dubai Healthcare City also introduced a new medical visa in January 2024, allowing treatment centers to apply for permits on behalf of patients for stays of up to six months. This move bolsters Dubai’s reputation as a medical tourism hotspot.

The city welcomed 674,000 medical tourists in 2022, generating $270 million in revenue. Wellness tourism is also booming in the UAE, with visitors spending $5.4 billion in 2022—almost double the amount spent in 2020.

Innovation At The Forefront

The UAE’s innovative spirit continues to propel its rise as a medical tourism hub. In 2024, HealthStay.io, the world’s first AI-powered medical tourism solution, launched in partnership with Dubai Health Experience. This startup, part of the Mohammed Bin Rashid Innovation Fund’s Accelerator Program, uses artificial intelligence to automate the medical tourism journey, including selecting treatments and booking appointments.

“The launch of HealthStay.io is a direct result of the support from DXH and DHA, helping us transform Dubai into a global healthcare tourism leader,” said Ruairi Tubrid, co-founder of HealthStay.io. Fatima Yousif Alnaqbi, MBRIF representative, emphasized the importance of accelerator programs in supporting innovative solutions that elevate the UAE’s standing as a center of excellence in healthcare.

Government Commitment To Healthcare Excellence

The UAE’s rapid growth in medical tourism is rooted in its consistent focus on healthcare improvement. Key strategies such as the Emirates Health Services Innovation Strategy 2023-2026 and the National Strategy for Wellbeing 2031 aim to enhance residents’ quality of life and elevate the nation’s healthcare offerings.

Compared to its Gulf Cooperation Council (GCC) counterparts, the UAE leads in healthcare expenditure growth. Projections from Alpen Capital estimate that healthcare spending will reach $30.7 billion by 2027, reflecting the nation’s ongoing dedication to strengthening its healthcare infrastructure. As a result, the UAE continues to attract international patients seeking top-tier medical services.

The Future Forbes Realty Global Properties

Tesla Renames Full Self-Driving In Europe As Regulators Push Back On Branding

by THEFUTURE.TEAM

October 12, 2026

Tesla is facing growing scrutiny over how it markets its Full Self-Driving (FSD) software in Europe, where regulators have questioned whether the name accurately reflects the technology’s capabilities. German authorities described the original branding as “somewhat misleading,” arguing that it could give drivers an exaggerated impression of the system’s autonomy.

Despite its name, FSD remains a driver-assistance system that requires drivers to stay attentive and ready to take control.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Regulatory Pressure Drives A Branding Shift

Germany’s Federal Ministry of Transport said the FSD name suggested a level of autonomy the software does not provide. The dispute highlights the tension between automakers’ marketing ambitions and regulators’ efforts to ensure that product names reflect actual capabilities.

In the United States, Tesla continues to offer the package as Full Self-Driving (Supervised), with a subscription priced at $99 per month. In Europe, its expansion depends on regulatory approval across multiple markets, making compliance and product descriptions increasingly important.

Europe Is Key To Tesla’s Autonomy Plans

Tesla has pushed European regulators, particularly in the Netherlands, to accelerate approval of its advanced driver-assistance software. Europe is an important market for the company as electric vehicle demand improves in parts of the region and Tesla seeks to recover from a previous sales downturn.

However, the approval process has attracted criticism. Reuters has reported that Tesla’s lobbying efforts have, in some cases, led regulators to reduce the intensity of safety testing and reviews, raising questions about the balance between commercial interests and public oversight.

U.S. Investigations Add To Safety Concerns

Tesla’s FSD system is also under investigation in the United States. The National Highway Traffic Safety Administration is examining its performance in conditions including fog and intense sunlight, as well as whether the software has contributed to traffic violations and collisions.

Legal challenges have added to the pressure. In December 2025, a California judge found that Tesla had engaged in deceptive marketing by implying that Autopilot and FSD were fully automated. Tesla has since countersued the California Department of Motor Vehicles in an effort to overturn the state’s “false advertiser” designation. The case remains pending.

Experts Question Transparency Of Approvals

Missy Cummings, an autonomous systems expert and engineering professor at George Mason University, argued that changing the branding does little to resolve the underlying safety concerns. In comments to CNBC, she questioned whether European regulators were adequately considering ongoing U.S. investigations into Tesla’s software.

“The EU is struggling to keep up in the AI marketplace,” Cummings said. “Musk sees this and is definitely bullying them as a result.”

She also criticised the Dutch vehicle regulator, RDW, for approving FSD in Europe based on what she described as “secretive data,” arguing that the public should have greater transparency around approvals for AI-powered transportation systems.

Tesla and RDW did not immediately respond to requests for comment.

Tesla Reports 1.48 Million Active FSD Subscriptions

In its second-quarter earnings update, Tesla reported 1.48 million active FSD subscriptions but did not disclose how many involved free trials or promotional offers. The omission makes it difficult to assess the product’s paid adoption accurately.

As autonomy remains an important part of Tesla’s long-term business strategy, the company faces challenges extending beyond technology development. Regulators are scrutinising both the software’s safety and the claims used to market it, keeping questions about capability, oversight and consumer trust at the centre of the debate.

Breaking news